导师信息

韩雅玲

院系名称:中国人民解放军沈阳军区总医院

担任职务:中国工程院院士

专业职称:教授、主任医师

导师类别:博士生导师

导师代码:

一级学科码: 1002        一级学科名称: 临床医学

二级学科码:100201       二级学科名称:内科学

研究方向

心血管病

所在科室

心血管病

个人简介

韩雅玲教授,中国工程院院士(2013年当选),著名心血管病专家,主任医师、教授,医学博士,博士生导师,现任沈阳军区总医院终身荣誉院长、全军心血管病研究所所长、心血管内科主任,全军心血管急重症救治重点实验室主任。为美国心脏学院专科会员(FACC)、欧洲心脏协会专科会员(FESC);中华医学会心血管病学分会候任主任委员、中国医师协会心内科医师分会候任会长、全军心血管内科专业委员会顾问、辽宁省医学会心血管病学分会主任委员、辽宁省医师协会内科医师分会会长、全军医学科技委员会常委和内科学领域委员会副主任委员, 美国《Circulation》杂志编委、英国《Cardiovascular Therapeutics》杂志副主编,《临床军医杂志》主编、《中国介入心脏病学杂志》执行主编、《中华医学杂志》(英文版)、《中华心血管病杂志》、《解放军医学杂志》、《解放军医药杂志》、《中华老年多器官疾病杂志》英文版、《中国介入心脏病学杂志》、《中华保健医学杂志》、《中国实用内科杂志》和《Military Medical Research》副主编。
韩雅玲院士以第一完成人承担国家自然科学重点基金、国家重大新药创制创新药物研究开发技术平台建设课题、国家“十二五”科技支撑计划项目、国家“十三五”慢病重点专项、军队“十一五”、“十二五”重点攻关课题、军事医学专项攻关课题等30余项。以第一或通讯作者发表论文500余篇,其中SCI期刊发表论著140余篇(最高影响因子37.6,发表于美国JAMA杂志),主编出版专著18部。
韩雅玲院士的主要学术贡献和技术专长为复杂危重缺血性心脏病的介入治疗和抗血栓治疗。1997年享受政府特殊津贴,曾被评为国家卫生部“中青年医学科技之星”、全国优秀科技工作者、全国“三八”红旗手,荣立一等功、二等功各1次、三等功8次。是中共十六大代表和第十一届、十二届全国政协委员。

教育与工作经历

已结题科研项目

在研项目

指导的研究生获得奖励

代表学术论文

1.Liang M, Rong J, Sun J, Yao T, Xuan F, Zhao L, Li F, Wang X, Han Y. A mobile minimally invasive interventional shelter: a new answer to on-spot emergency treatment of large arterial injuries? Scand J Trauma Resusc Emerg Med. 2015 Sep 4;23(1):63.
2.Han Y, Li Y, Stone GW. Varying Responses to Antithrombotic Treatment by Race/Ethnicity--Reply. JAMA, 2015 Aug 11;314(6):625.
3.Liang Y, Yu H, Zhou W, Xu G, Sun YI, Liu R, Wang Z, Han Y. Left Ventricular Lead Placement Targeted at the Latest Activated Site Guided by Electrophysiological Mapping in Coronary Sinus Branches Improves Response to Cardiac Resynchronization Therapy. J Cardiovasc Electrophysiol. 2015 Aug 7. doi: 10.1111/jce.12771. [Epub ahead of print]
4.Sun M, Tian X, Liu Y, Zhu N, Li Y, Yang G, Peng C, Yan C, Han Y. Cellular repressor of E1A-stimulated genes inhibits inflammation to decrease atherosclerosis in ApoE(-/-) mice. J Mol Cell Cardiol. 2015 Sep;86:32-41.
5.Han Y, Guo J, Zheng Y, Zang H, Su X, Wang Y, Chen S, Jiang T, Yang P, Chen J, Jiang D, Jing Q, Liang Z, Liu H, Zhao X, Li J, Li Y, Xu B, Stone GW; BRIGHTInvestigators. Bivalirudinvs heparin with or without tirofiban during primarypercutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA. 2015 Apr 7;313(13):1336-46.
6.Zhang X, Feng X, Cai W, Liu T, Liang Z, Sun Y, Yan C, Han Y. Chemokine CX3CL1 and its receptor CX3CR1 are associated with human atherosclerotic lesionvolnerability. Thromb Res. 2015 Jun;135(6):1147-53.
7.Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. Chinese experts recommendation on the monitoring and management of variability in responsiveness to antiplatelet therapy. Eur Heart J Suppl. 2015:17: B5–B12(Prof. Han Y as Correspondence author).
8.Li Y, Han Y, Guan S, Sun Y, et al. Optimal- vs. standard-antiplatelet therapy on platelet function and long-term clinical outcomes in patients with high on-treatment platelet reactivity: 2-year outcomes of the multicentre, randomized Optimal-antiPlatelet Therapy (OPT) trial. Eur Heart J Suppl. 2015:17: B23–B31.
9.Qiao B, Deng J, Li Y, Wang X, Han Y. Rosuvastatin attenuated contrast-induced nephropathy in diabetes patients with renal dysfunction. Int J ClinExp Med. 2015Feb 15;8(2):2342-9.
10.Zhang J, Li Y, Tao GZ, Chen Y, Hu T, Cao X, Jing Q, Wang X, Ma Y, WangG, Liu H, Wang B, Xu K, Li J, Deng J, Han Y. Short-term rosuvastatin treatment for the prevention of contrast-induced acute kidney injury in patients receiving moderate or high volumes of contrast media: a sub-analysis of the TRACK-D study. Chin Med J (Engl). 2015 Mar 20;128(6):784-9.
11.Wang XZ, Xu K, Li Y, Jing QM, Liu HW, Zhao X, Wang G, Wang B, Ma YY, Chen SL, Han Y. Comparison of the efficacy of drug-eluting stents versus bare-metalstents for the treatment of left main coronary artery disease. Chin Med J (Engl).2015 Mar 20;128(6):721-6.
12.Peng C, Pei H, Wei F, Tian X, Deng J, Yan C, Li Y, Sun M, Zhang J, Liu D,Rong J, Wang J, Gao E, Li S, Han Y. Cellular repressor of E1A-stimulated geneoverexpression in bone mesenchymal stem cells protects against rat myocardialinfarction. Int J Cardiol. 2015 Mar 15;183:232-41.
13.Deng J, Wu G, Yang C, Li Y, Jing Q, Han Y. Rosuvastatin attenuatescontrast-induced nephropathy through modulation of nitric oxide, inflammatoryresponses, oxidative stress and apoptosis in diabetic male rats. J Transl Med.2015 Feb 12;13(1):53.
14.Li S, Deng J, Wang X, Zhao X, Han Y. Efficiencies of intracoronary sodiumnitroprusside on fractional flow reserve measurement. Int J Clin Exp Med. 2015Feb 15;8(2):2679-83.
15.Zhu H, Li Y, Guan S, Li J, Wang XZ, Jing Q, Wang Z, Han Y. Efficacy and safety of individually tailored antiplatelet therapy in patients with acutecoronary syndrome after coronary stenting: a single center, randomized,feasibility study. J Geriatr Cardiol. 2015 Jan;12(1):23-9.
16.Wang G, Sun Z, Jin Q, Xu K, Li Y, Wang X, Ma Y, Liu H, Zhao X, Wang B, DengJ, Guan S, Ge M, Wang X, Xu B, Han Y. First-in-man study evaluating the safetyand efficacy of a second generation biodegradable polymer sirolimus-eluting stentin the treatment of patients with de novo coronary lesions: clinical,Angiographic, and OCT outcomes of CREDIT-1. Catheter CardiovascInterv. 2015Mar;85Suppl 1:744-51.
17.Rong J, Liang M, Xuan F, Sun J, Zhao L, Zhen H, Tian X, Liu D, Zhang Q, Peng C, Yao T, Li F, Wang X, Han Y, Yu W. Alginate-calcium microsphereloaded with thrombin: a new composite biomaterial for hemostatic embolization.Int J Biol Macromol. 2015 Apr;75:479-88.
18.Yan C, Li Y, Tian X, Zhu N, Song H, Zhang J, Sun M, Han Y.CREG1 ameliorates myocardial fibrosis associated with autophagy activation and Rab7 expression.Biochim Biophys Acta. 2015 Feb;1852(2):353-64.
19.Li Y, Yan C, Tian X, Peng C, Han Y. The Change of Cellular Repressor of E1A-stimulated Genes During Carotid Vascular Remodeling. Prog Biochem Biophys, 2015, 42(2):161-168.
20.Wang Z, Ouyang J, Liang Y, Jin Z, Yang G, Liang M, Li S, Yu H, Han Y.Focal Atrial Tachycardia Surrounding the Anterior Septum: Strategy for Mapping and Catheter Ablation.CircArrhythmElectrophysiol. 2015 Apr 23. pii: CIRCEP.114.002281.
21.Liu D, Zhang X, Yan CH, Li Y, Tian X, Zhu N, Rong J, Peng C, Han Y.MicroRNA-495 regulates the proliferation and apoptosis of human umbilical vein endothelial cells by targeting chemokine CCL2. Thromb Res. 2015 Jan;135(1):146-54.

获奖情况

以第一作者获得何梁何利基金科学与技术进步奖1项(2015)、国家科技进步二等奖2项(2008、2013)、军队科技进步一等奖1项(2015)、军队医疗成果一等奖2项(2002、2012)、辽宁省科技进步一等奖3项(1995、2007、2016),以及辽宁医学科技一等奖(2014)、军队医疗成果二等奖(2007)、辽宁省科技进步二等奖(2011)和中华医学科技进步二等奖(2007)各1项

E-mail

备  注

快速导航